DXCM DEXCOM INC.

Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States

, Inc. () announced today the Dexcom G6 Continuous Glucose Monitoring (CGM) System is now available at Veterans Affairs (VA) pharmacies, improving access to CGM and empowering veterans with diabetes to better manage their condition. Veterans with Type 1 or Type 2 diabetes who meet the qualifying coverage criteria have 100% of the costs of Dexcom G6 covered by the VA.

“Previously, VA prescriptions for Dexcom CGM were filled through the Durable Medical Equipment channel, which can result in additional costs and potential delays for patients in obtaining the system and its supplies. In the past, patients may have waited two to six weeks for supplies, but now VA patients who are prescribed Dexcom G6 will be able to start CGM and refill supplies in just two to three days at their local VA pharmacy,” said Kevin Sayer, chairman, president and CEO of Dexcom. “Veterans have made incredible sacrifices on behalf of our country, and they deserve to have access to the most innovative technology that can help make diabetes management easier and improve their health.”

Veterans are 2.5 times more likely to have diabetes than the general population—with one in four veterans diagnosed with diabetes. The VA’s new streamlined prescription and pharmacy process for Dexcom G6 CGM will make it easier for veterans to obtain and adhere to CGM, helping to improve diabetes management for this important population.

“Easier access to CGM at the pharmacy is a big win for veterans with diabetes. Research continues to show CGM should be the standard of care for any diabetes patient on intensive insulin therapy,” said Dhiren Patel, PharmD, CDCES, BC-ADM, BCACP, an endocrine clinical pharmacy specialist. “Dexcom G6 has a number of highly beneficial features including predictive low alerts to help avoid dangerous low blood sugar events, time-in-range reports, and remote monitoring capabilities that allow patients to share their glucose data in real time with up to 10 followers.”

Dexcom G6 features and benefits:

  • Fingerstick elimination – No fingersticks needed for calibration or diabetes treatment decisions*
  • Continuous glucose readings – Automatically sends glucose readings to a Dexcom receiver or compatible smart device every five minutes
  • Mobile app and sharing – Compatibility with smart device apps allows for sharing glucose information with up to 10 people for added support
  • Customizable alarms and alerts – Personalized alert schedule immediately warns the wearer of pending dangerous high and low blood sugars
  • Easy sensor applicator – One-touch, simple insertion
  • Discreet and low profile – Transmitter with a 28% lower profile than previous generation Dexcom CGMs makes the device comfortable and easy to wear under clothing
  • Acetaminophen blocking – Allows for more accurate glucose readings with no medication interference
  • Predictive low alert – Predicts hypoglycemia before it hits to help avoid dangerous low blood sugar events§
  • Extended 10-day sensor – Allows for 43% longer wear than previous generation Dexcom CGMs

The new government contract and procurement pathway at the VA for Dexcom G6 makes prescribing Dexcom CGM now more cost effective and efficient for the VA.

Dexcom G6 is 100% covered for VA patients who meet the following coverage criteria:

  • Has diabetes mellitus
  • Requires an intensive insulin regimen (e.g. ≥3 injections a day, or insulin pump) to achieve desired glycemic control (target range) based upon shared-decision making)
  • Requires frequent blood glucose monitoring (≥4 or more times a day)
  • Has the knowledge and skill set necessary to successfully utilize CGM
  • Agrees to ongoing medical appointments with multidisciplinary team at least every six months to assess the adherence and benefit derived from CGM
  • Meets at least one of the following criteria:
    • At risk for hypoglycemia
    • Unable to meet glycemic control despite adherence to the treatment regimen
    • Performing job-related activities where a hypoglycemic event could put them at risk of harm
    • Unable to perform self-monitoring of blood glucose due to disability or disease

Patients and VA healthcare providers can learn more about starting or prescribing Dexcom CGM through the VA at .

About DexCom, Inc.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit .

* If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

For a list of compatible devices, visit /compatibility.

Separate Follow App required.

§The urgent low soon can warn you in advance of severe hypoglycemia—allowing you time to take appropriate action before it happens.

Dexcom, Dexcom G6, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries. ©2019 Dexcom Inc. All rights reserved.

EN
22/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DEXCOM INC.

Dexcom Inc: 3 directors

Two Directors at Dexcom Inc sold 3,250 shares at between 82.800USD and 83.129USD. The significance rating of the trade was 45/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

OSK OSHKOSH CORP
DXCM DEXCOM INC.
XRAY DENTSPLY SIRONA INC.
WING WINGSTOP INC.
VRTS VIRTUS INVESTMENT PARTNERS INC.
UHS UNIVERSAL HEALTH SERVICES INC. CLASS B
STKS ONE GROUP HOSPITALITY
SNPS SYNOPSYS INC.
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SFST SOUTHERN FIRST BANCSHARES
RGNX REGENXBIO INC.
RCKY ROCKY BRANDS
PRGO PERRIGO CO. PLC
MPWR MONOLITHIC POWER SYSTEMS INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
IRM IRON MOUNTAIN INC.
GPC GENUINE PARTS COMPANY
GD GENERAL DYNAMICS CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CROX CROCS INC.
CAL CALERES INC.
BKE BUCKLE INC.
ASC ARDMORE SHIPPING
AMOT ALLIED MOTION TECHNOLOGIES
ACAD ACADIA PHARMACEUTICALS INC.
SBL SAFE BULKERS INC.
LPG DORIAN LPG
MEG. MEG ENERGY CORP.
MDU MDU RESOURCES GROUP INC
NAT NORDIC AMERICAN TANKERS LIMITED
EVTC EVERTEC INC.
FSLR FIRST SOLAR INC.
IONS IONIS PHARMACEUTICALS INC.
NMIH NMI HOLDINGS INC. CLASS A
AGYS AGILYSYS INC.
SJM J.M. SMUCKER COMPANY
FIZZ NATIONAL BEVERAGE CORP.
NHC NATIONAL HEALTHCARE CORP.
INSW INTERNATIONAL SEAWAYS INC.
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
CELH CELSIUS HOLDINGS INC.
AMD ADVANCED MICRO DEVICES INC.
TTEC TTEC HOLDINGS INC.
AVGO BROADCOM INC.
ST SENSATA TECHNOLOGIES HOLDING PLC
ELAN ELANCO ANIMAL HEALTH INC.
MEC MAYVILLE ENGINEERING
DELL DELL TECHNOLOGIES INC CLASS C
CSTM CONSTELLIUM SE CLASS A
OI O-I GLASS INC
BWMN BOWMAN CONSULTING GROUP LTD
DINO HOLLYFRONTIER CORP
EVEX EVE HOLDING INC
SPXC SPX TECHNOLOGIES INC
WEST WESTROCK COFFEE COMPANY LLC
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
AGEN AGENUS INC.
ARDT ARDENT HEALTH PARTNERS INC
PCT PROVIDENT CAP TR II SKIS 8.75%29
MKTW MARKETWISE INC
 PRESS RELEASE

Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medi...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insights into access to care and perceptions of diabetes technology. During the conference, first-ever accuracy a...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch